Clinical Trial Update: An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating azetukalner for bipolar depression in bipolar I or II disorder. Enrollment is ongoing by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Bipolar Ii Disorder

Drugs mentioned

• Azetukalner

Snippet

Sponsor: Xenon Pharmaceuticals Inc. | Conditions: Bipolar Depression, Bipolar I Disorder | Phase 3 | Status: ENROLLING_BY_INVITATION